Literature DB >> 32533389

Comparing the fate of brain metastatic breast cancer cells in different immune compromised mice with cellular magnetic resonance imaging.

Natasha N Knier1,2, Amanda M Hamilton3, Paula J Foster3,4.   

Abstract

Metastasis is the leading cause of mortality in breast cancer patients, with brain metastases becoming increasingly prevalent. Studying this disease is challenging due to the limited experimental models and methods available. Here, we used iron-based cellular MRI to track the fate of a mammary carcinoma cell line (MDA-MB-231-BR) in vivo to characterize the growth of brain metastases in the nude and severely immune-compromised NOD/SCID/ILIIrg-/- (NSG) mouse. Nude and NSG mice received injections of iron-labeled MDA-MB-231-BR cells. Images were acquired with a 3T MR system and assessed for signal voids and metastases. The percentage of signal voids and the number and volume of metastases were quantified. Ex vivo imaging of the liver, histology, and immunofluorescence labeling was performed. Brain metastases grew more rapidly in NSG mice. At day 21 post cell injection, the average number of brain tumors in NSG mice was approximately four times greater than in nude mice. The persistence of iron-labeled cells, visualized as signal voids by MRI, was also examined. The percentage of voids decreased significantly over time for both nude and NSG mice. Body images revealed that the NSG mice also had metastases in the liver, lungs, and lymph nodes while tumors were only detected in the brains of nude mice. This work demonstrates the advantages of using the highly immune-compromised NSG mouse to study breast cancer metastasis, treatments aimed at inhibiting metastasis and outgrowth of breast cancer metastases in multiple organs, and the role that imaging can play toward credentialing these models that cannot be done with other in vitro or histopathologic methods alone.

Entities:  

Keywords:  Brain metastasis; Breast cancer; Cellular magnetic resonance imaging; Iron oxide nanoparticles; Mouse models

Mesh:

Year:  2020        PMID: 32533389     DOI: 10.1007/s10585-020-10044-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

Review 1.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

2.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 3.  Brain metastases: epidemiology and pathophysiology.

Authors:  Igor T Gavrilovic; Jerome B Posner
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 4.  Understanding and treating triple-negative breast cancer.

Authors:  Carey Anders; Lisa A Carey
Journal:  Oncology (Williston Park)       Date:  2008-10       Impact factor: 2.990

Review 5.  Recent trends in epidemiology of brain metastases: an overview.

Authors:  Emeline Tabouret; Olivier Chinot; Philippe Metellus; Agnès Tallet; Patrice Viens; Anthony Gonçalves
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

6.  Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

Authors:  Florian Heitz; Philipp Harter; Hans-Joachim Lueck; Annette Fissler-Eckhoff; Fatemeh Lorenz-Salehi; Stefanie Scheil-Bertram; Alexander Traut; Andreas du Bois
Journal:  Eur J Cancer       Date:  2009-07-28       Impact factor: 9.162

7.  Breast cancer: metastatic patterns and their prognosis.

Authors:  V Patanaphan; O M Salazar; R Risco
Journal:  South Med J       Date:  1988-09       Impact factor: 0.954

Review 8.  Tumor cell dormancy: implications for the biology and treatment of breast cancer.

Authors:  T Fehm; V Mueller; R Marches; G Klein; B Gueckel; H Neubauer; E Solomayer; S Becker
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 9.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

10.  Tumour dormancy in breast cancer: an update.

Authors:  Muriel Brackstone; Jason L Townson; Ann F Chambers
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  3 in total

1.  A method for the efficient iron-labeling of patient-derived xenograft cells and cellular imaging validation.

Authors:  Natasha N Knier; Veronica P Dubois; Yuanxin Chen; John A Ronald; Paula J Foster
Journal:  J Biol Methods       Date:  2021-09-03

Review 2.  An Insight into Molecular Targets of Breast Cancer Brain Metastasis.

Authors:  Mohammed Kaleem; Mahmood Hassan Dalhat; Lubna Azmi; Turky Omar Asar; Wasim Ahmad; Maimonah Alghanmi; Amal Almostadi; Torki A Zughaibi; Shams Tabrez
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

Review 3.  Preclinical Models of Brain Metastases in Breast Cancer.

Authors:  Natasha N Knier; Sierra Pellizzari; Jiangbing Zhou; Paula J Foster; Armen Parsyan
Journal:  Biomedicines       Date:  2022-03-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.